Ionis Pharmaceuticals IONS Federal
Federal at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CurrentFederalTaxExpenseBenefit.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's federal.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's federal?
- Ionis Pharmaceuticals (IONS) reported federal of -$253.75K in Q4 2025.
- How has Ionis Pharmaceuticals's federal changed year-over-year?
- Ionis Pharmaceuticals's federal increased by 81.5% year-over-year, from -$1.37M to -$253.75K.
- What is the long-term trend for Ionis Pharmaceuticals's federal?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's federal has grown at a -83.2% compound annual growth rate (CAGR), from $35.86M to -$1.02M.
- What does federal mean?
- The current period's income tax expense owed to the federal government.
- How do you interpret federal?
- Changes reflect fluctuations in taxable income or changes in federal tax rates and credits.
- How does federal compare across companies?
- Standard line item in the tax reconciliation note for all U.S. public companies.